A universal vaccine for influenza targeting T cells
Universal T cell targeted influenza vaccine
This study is working on a new flu vaccine that helps your immune system recognize and fight off different strains of the virus, so it can protect you better now and in the future, no matter how the virus changes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saint Louis University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10685570 on NIH RePORTER |
What this research studies
This research aims to develop a universal influenza vaccine that targets T cells to provide broader and more effective protection against various strains of the virus. By utilizing advanced immunoinformatic tools, the researchers will identify conserved T cell epitopes that can stimulate immune responses in a majority of the population. The goal is to create a vaccine that not only protects against currently circulating strains but also offers cross-protection against future variants. This approach seeks to overcome the limitations of traditional vaccines, which often vary in effectiveness from year to year.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk for influenza, such as the elderly, young children, and those with compromised immune systems.
Not a fit: Patients who are not at risk for influenza or those who have already received a seasonal flu vaccine may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective influenza vaccine that provides long-lasting protection against multiple strains of the virus.
How similar studies have performed: Previous research has shown promise in developing T cell-based vaccines for influenza, indicating that this approach has potential for success.
Where this research is happening
Saint Louis, United States
- Saint Louis University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Hoft, Daniel F. — Saint Louis University
- Study coordinator: Hoft, Daniel F.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.